Pharmaceutical industry – Page 4
-
OpinionWomen are not just another confounding factor in drug development
Ignoring physiological differences between the sexes is indefensible
-
OpinionImproving women’s health research will benefit everyone
Fixing the inequality is morally just, and economically sound
-
BusinessTrade deals stave off Trump’s tariffs temporarily
Initial agreements with China and UK have paused trade war, but uncertainty reigns
-
OpinionRebuilding pharma supply chains
Multinationals are promising huge US investments, but it’s not all because of Trump’s policies
-
OpinionIn search of truth and rules
To codify and predict ever more complex phenomena is one of science’s great drivers
-
BusinessMerck KGaA to buy cancer specialist SpringWorks
$3.9 billion deal boosts Merck’s pipeline as it faces patent expiries
-
BusinessGilead settles US HIV drug kickback lawsuit
Firm will pay $202 million to federal and state governments
-
WhitepaperOptimise drug discovery: predicting transporter-mediated drug interactions
Learn how in vitro models, biomarkers and modelling can improve prediction of drug interactions and toxicity – reducing false positives and unnecessary clinical studies
-
BusinessFree energy methods and digital transformation of drug discovery
Synergistic application of AI-based generative chemistry and free energy methods streamlines molecule discovery and optimisation
-
OpinionPolymorphs matter – especially when they might disappear
Disappearing polymorphs offer a fascinating example of the dark arts of crystallisation
-
NewsFears grow over the future of mRNA vaccine research in the US
Researchers working on mRNA vaccines fear federal funding might be halted, with many looking to move projects abroad
-
BusinessAcceptable levels of (epi)genetic engineering
Amplifying or silencing genes may be preferable to permanently changing genetic code
-
OpinionThe value of good software extends beyond its cost
Whether third-party or built in-house, thoughtful design and implementation can improve workflows and make science more inclusive
-
BusinessGovernment reduces UK Reach fees by ‘£40 million’
Registration fees for most chemicals reduced, but uncertainty remains over safety data requirements
-
BusinessEpigenetic editors enter clinical trials
New wave of precision medicines amplify or silence genes, without altering genetic code
-
BusinessTrump’s new tariffs threaten the chemicals sector
Broad and high tariffs could mean severe job losses and supply chain disruption for chemistry-using industries
-
OpinionTrump’s tariff stand-off
Piling cost and complexity to stretched global supply chains will hit industries hard
-
BusinessJ&J’s third talc bankruptcy settlement attempt denied
Company says it will return to courts to fight talc cancer claims
-
BusinessUS regulatory chief’s resignation raises alarms in biotech industry
FDA vaccines and biologicals centre director, Peter Marks, clashed with health secretary Robert F Kennedy Jr
-
OpinionWelcome to the MegaPharm target selection and project resourcing meeting
Overheard recently in a seminar room near you…